Literature DB >> 21868085

The cryoglobulinaemias.

Manuel Ramos-Casals1, John H Stone, Maria C Cid, Xavier Bosch.   

Abstract

Cryoglobulins are immunoglobulins that precipitate in vitro at temperatures less than 37°C and produce organ damage through two main pathways: vascular sludging (hyperviscosity syndrome, mainly in type I cryoglobulinaemia) and immune-mediated mechanisms (principally vasculitis, in mixed cryoglobulinaemia). Cryoglobulinaemia is associated with many illnesses, which can be broadly grouped into infections, autoimmune disorders, and malignancies; the most common cause is infection with hepatitis C virus. Mixed cryoglobulinaemic syndrome is diagnosed when a patient has typical organ involvement (mainly skin, kidney, or peripheral nerve) and circulating cryoglobulins. Cutaneous purpura is the most common manifestation of cryoglobulinaemic vasculitis. The most frequently affected internal organs are the peripheral nerves, kidneys, and joints. The course varies widely and prognosis is influenced by both cryoglobulinaemic damage to vital organs and by comorbidities associated with underlying diseases. More than 90% of cases of cryoglobulinaemia have a known underlying cause; therefore treatment is focused on the cause of the disorder rather than merely symptomatic relief. Studies suggest that both combined or sequential antiviral therapies and targeted biological treatments might be more effective than monotherapy.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21868085     DOI: 10.1016/S0140-6736(11)60242-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  114 in total

1.  Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.

Authors:  Meghan E Sise; Allyson K Bloom; Jessica Wisocky; Ming V Lin; Jenna L Gustafson; Andrew L Lundquist; David Steele; Michael Thiim; Winfred W Williams; Nikroo Hashemi; Arthur Y Kim; Ravi Thadhani; Raymond T Chung
Journal:  Hepatology       Date:  2015-12-11       Impact factor: 17.425

Review 2.  Management of patients with hepatitis C infection and renal disease.

Authors:  Chalermrat Bunchorntavakul; Monthira Maneerattanaporn; Disaya Chavalitdhamrong
Journal:  World J Hepatol       Date:  2015-02-27

Review 3.  Dermatological and immunological conditions due to nerve lesions.

Authors:  D Bove; A Lupoli; S Caccavale; V Piccolo; E Ruocco
Journal:  Funct Neurol       Date:  2013 Apr-May

Review 4.  Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders.

Authors:  Deng-Ho Yang; Ling-Jun Ho; Jenn-Haung Lai
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 5.  The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases.

Authors:  Sanjeev Sethi; S Vincent Rajkumar; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2018-04-27       Impact factor: 10.121

Review 6.  Peripheral neuropathies in rheumatic disease--a guide to diagnosis.

Authors:  Jean-Michel Vallat; Magalie Rabin; Laurent Magy
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

7.  Pulmonary hemorrhage in cryoglobulinemia.

Authors:  Gordon Kirkpatrick; Tiffany Winstone; Pearce Wilcox; Stephan Van Eeden
Journal:  Can Respir J       Date:  2014-12-10       Impact factor: 2.409

Review 8.  Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.

Authors:  Shveta S Motwani; Leal Herlitz; Divya Monga; Kenar D Jhaveri; Albert Q Lam
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

9.  Prognostic value of Sjögren's syndrome autoantibodies.

Authors:  R Hal Scofield; Anum Fayyaz; Biji T Kurien; Kristi A Koelsch
Journal:  J Lab Precis Med       Date:  2018-10-30

10.  Pathological crystallization of human immunoglobulins.

Authors:  Ying Wang; Aleksey Lomakin; Teru Hideshima; Jacob P Laubach; Olutayo Ogun; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson; George B Benedek
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.